wolfsilikon.blogg.se - Iota carrageenan

IOTA CARRAGEENAN TRIAL
IOTA CARRAGEENAN PLUS

To determine whether carrageenan nasal and throat spray reduces the severity and/or duration of infection with other respiratory viruses.

To determine whether carrageenan nasal and throat spray reduces the risk of infection with other respiratory viruses.

To determine whether carrageenan nasal and throat spray reduces the severity and/or duration of COVID-19 infection.

The primary objective is to determine whether carrageenan nasal and throat sprays reduce the risk of COVID-19 infection. Condition or diseaseĭevice: Carrageenan nasal and throat spray Device: Saline nasal and throat spray Secondary objectives are to determine if carrageenan sprays reduce the clinical severity of COVID-19 and symptomatic acute respiratory infection of other aetiologies (non-SARS-CoV-2). The study's primary objective is the prevention of COVID-19 infection, confirmed by PCR swab or documented seroconversion.

IOTA CARRAGEENAN PLUS

Participants (n=240) will be randomly allocated to either the treatment arm (verum Coldamaris plus, 0.12% iota-carrageenan plus 0.04% Kappa-Carrageenan in 0.5% saline) or placebo (Coldamaris sine, saline 0.5%) arm.

IOTA CARRAGEENAN TRIAL

ICE-COVID a randomised, double blind, placebo-controlled phase III trial of the prophylactic efficacy of iota-carrageenan nasal and throat spray in preventing COVID-19 illness in at risk healthcare professionals. Carrageenan mimics cell surface HS, thereby trapping the virus to allow mucociliary clearance and has demonstrated anti-viral activity in-vitro and in a number of common cold clinical trials when administered as a nasal spray. SARS-CoV-2 is a positive-sense single-stranded enveloped RNA virus which transmits via droplets, aerosols and direct contact, to reach their target naso- and oropharyngeal epithelial cells through initial electrostatic interactions to cell surface heparan sulphate (HS) proteoglycans.

Key workers are at high risk of exposure highlighting the need for effective preventative strategies. There is currently no proven treatment, chemoprophylaxis or vaccine against COVID-19, which exhibits a wide clinical spectrum from asymptomatic carriage to mild upper respiratory tract infection, severe viral pneumonia to acute respiratory distress syndrome and death. The current COVID-19 pandemic is the biggest global healthcare challenge in the last century, and the number of cases in the next 12 months is likely to increase. Why Should I Register and Submit Results?.